-
Mashup Score: 0HOME - Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy - 1 year(s) ago
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HOME - Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy - 1 year(s) ago
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Get ready for practice-changing evidence for your patients with #CRPC. @JuddMoul, @DrRanaMcKay, @zklaassen_md & Dr. Paul Sieber will place new developments into clinical context during our breakfast symposium at #AUA23. Register now: https://t.co/Q1PtOmcpvd #gotoPER #GUcancer https://t.co/tECucIhMYC
-
-
Mashup Score: 0Prostate Cancer Drug Shortage Leaves Some With Uncertainty - 1 year(s) ago
The radioligand treatment Pluvicto is in short supply, which could extend for months, according to its manufacturer Novartis.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A radioligand treatment approved for certain men with metastatic castration-resistant #prostatecancer is in short supply because of manufacturing and delivery issues, according to the FDA. #CRPC https://t.co/64nG1KbvqC
-
-
Mashup Score: 0HOME - Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy - 1 year(s) ago
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Announcing our complimentary breakfast session on maximizing clinical outcomes for patients with CRPC at AUA 2023. Reserve your spot now: https://t.co/uiFOG1E2U0 #gotoPER #GUcancer #prostatecancer #CRPC #AUA https://t.co/xPLdRcHV6g
-
-
Mashup Score: 0Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff - 1 year(s) ago
Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Multidisciplinary care teams to optimize care of patients with bone metastatic #CRPC. @TDorffOnc @cityofhope and @CaPsurvivorship @DanaFarber join in this discussion on UroToday > https://t.co/VWewvkeIns https://t.co/Stwwyt80BW
-
-
Mashup Score: 0Long-Term Tolerability Reported With Darolutamide Use in Patients With Nonmetastatic CRPC - 1 year(s) ago
Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Long-Term Tolerability Reported With Darolutamide Use in Patients With Nonmetastatic CRPC #pcsm #prostatecancer #CRPC #oncology #Nursing #GU23 @AtlanticUrology https://t.co/nnVia8defd
-
-
Mashup Score: 2
ASCO GU 2023 Salvage pelvic radiation therapy, non-metastatic castrate-resistant prostate cancer (nmCRPC), anti-PSMA antibody J591 radiolabeled with 177Lu or 111In, ketoconazole, hydrocortisone, high-risk nmCRPC patients.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Randomized, double-blinded phase II study of ketoconazole, hydrocortisone, and anti-PSMA antibody J591 labeled with 177Lu or 111In in pts with high-risk M0 #CRPC. Presented by @DrScottTagawa @WeillCornell. @ASCO #GU23 written coverage by @rksayyid @UofT > https://t.co/WJ8Wik6Fz1 https://t.co/eGWRrkYsmt
-
-
Mashup Score: 0Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR Status - 1 year(s) ago
At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR Status #oncology #Nursing #prostatecancer #pcsm #CRPC #GU23 @neerajaiims @huntsmancancer https://t.co/YoZUyHx7gq
-
-
Mashup Score: 0ASCO GU 2023: Comparison of ctDNA Between African American and Caucasian Patients with CRPC Post Abiraterone And/or Enzalutamide - 1 year(s) ago
ASCO GU 2023, prostate cancer, castration resistant prostate cancer (CRPC), Comparison of ctDNA Between African American and Caucasian Patients with CRPC,abiraterone acetate, enzalutamide, genomic alteration, genomics in prostate cancer treatment.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Comparison of ctDNA between African American and Caucasian patients with #CRPC post abiraterone and/or enzalutamide. Presentation by Albert Jang, MD @TulaneMedicine. @ASCO #GU23 written coverage by @DrJonesNauseef @WeillCornell > https://t.co/cwwy4hv57f https://t.co/dlVuUVA3zw
-
-
Mashup Score: 0Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff - 1 year(s) ago
Tanya Dorff and Alicia Morgans discuss the importance of multidisciplinary care teams for patients with bone metastatic castration-resistant prostate cancer (mCRPC). The pair talk about the need for clear communication between physicians, radiation oncologists, and nuclear medicine physicians on the team, as well as the importance of the nursing and imaging staff. Dr. Dorff also stresses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Multidisciplinary care teams to optimize care of patients with bone metastatic #CRPC. @TDorffOnc @cityofhope and @CaPsurvivorship @DanaFarber join in this discussion on UroToday > https://t.co/VWewvkeIns https://t.co/ZcBrglbhrv
-
Join us at #AUA23 in Chicago this year for a complimentary breakfast symposium on #CRPC. Reserve your spot today: https://t.co/nr0npHlE9N #gotoPER #GUcancer @JuddMoul @DrRanaMcKay @zklaassen_md https://t.co/j4U77mqkQ8